Pax-5 protein expression in bladder cancer: a preliminary study that shows no correlation to grade, stage or clinical outcome

References

• Parker S L, Tong T, Bolden S, Wingo P A. Cancer statistics. CA Cancer J Clin 1997; 47: 5–27
   PubMed Web of Science ®Google Scholar
• Kiemeney L A, Witjes J A, Heijbroek, Verbeek A LM, Debriyne F MJ. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60–64
   PubMed Web of Science ®Google Scholar
• Hasui Y, Osada Y, Kitada S, Nishi S. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994; 43: 782–786
   PubMed Web of Science ®Google Scholar
• Vollmer R T, Humprey P A, Swanson P E, et al. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B2, epidermal growth factor receptor, and bcl-2. Cancer 1998; 82: 715–723
   PubMed Web of Science ®Google Scholar
• Tsujihashi H, Nakanishi A, Matsuda H, et al. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 1993; 145: 846–849
   Web of Science ®Google Scholar
• Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU International 2000; 85: 48–53
   PubMed Web of Science ®Google Scholar
• Robson E JD, He S J, Eccles M R. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 52: 52–62
   Web of Science ®Google Scholar
• Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol 2004; 22: 55–79
   PubMed Web of Science ®Google Scholar
• Torlakovic E, Torlakovic G, Nguyen P L, et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002; 26: 1343–1350
   PubMed Web of Science ®Google Scholar
• Tiacci E, Pileri S, Orleth A, et al. PAX5 expression in acute leukemias: higher B-lineage specifity than CD79a and selective association with t(8;21) acute myelogenous leukaemia. Cancer Res 2004; 64: 7399–7404
   PubMed Web of Science ®Google Scholar
• Babjuk M, Soukup V, Mares J, et al. Association of PAX5 expression with clinical outcome in patients with pTaT1 transitional cell carcinoma of the bladder. Urology 2006; 67: 756–761
   PubMed Web of Science ®Google Scholar
• Adshead J M, Ogden C W, Penny M A, Stuart E T, Kessling A M. The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. BJU International 1999; 83: 1039–1044
   PubMed Web of Science ®Google Scholar
• UICC. TNM Classification of Malignant Tumors6th ed. Wiley & Sons, New York 2002
   Google Scholar
• Mostofi F K, Sobin L H, Torloni H. Histological Typing of Urinary Bladder Tumors. World Health Organization, Geneva 1973
   Google Scholar
• Eble J, Sauter G, Epstein J I, Sesterhenn I A. Classification of Tumours. Pathology and Gentics of the Tumours of the Urinary System and Male Genital Organs. World Health Organization, Lyon 2004
   Google Scholar
• Smith J A, Labasky R F, Cockett A T, Fracchia J A, Montie J E, Rowland R G. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162: 1697–1701
   PubMed Web of Science ®Google Scholar
• Klopocki E, Kristiansen G, Wild P J, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004; 25: 641–649
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Saxena R, Zhang S, et al. Pax-5 immunoexpression in various types of benign and malignant tumors: a high-throughput tissue microarray analysis. J Clin Pathol 2007; 60: 709–714
   PubMed Web of Science ®Google Scholar
• Younis R T, Hesse S V, Anand V K. Evaluation of the utility and cost-effectiveness of obtaining histopathologic diagnosis on all routine tonsillectomy specimens. Laryngoscope 2000; 111: 2166–2169
   Web of Science ®Google Scholar
• Lang D, Powell S K, Plummer R S, Young K P, Ruggeri B A. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007; 73: 1–14
   PubMed Web of Science ®Google Scholar
• Robson E JD, He S J, Eccles M R. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 6: 52–62
   PubMed Web of Science ®Google Scholar
• Babjuk M, Soukup V, Mares J, et al. The expression of PAX5, p53 immunhistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol 2002; 34: 495–501
   PubMedGoogle Scholar
• Muratovska A, Zhou C, He S, Goodyer P, Eccles M R. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003; 22: 7989–7997
   PubMed Web of Science ®Google Scholar
• Torlakovic E, Slipicevic A, Robinson C, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol 2006; 126: 798–804
   PubMed Web of Science ®Google Scholar
• Gibson S E, Dong H Y, Advani A S, His E D. Expression of the B-cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation. Am J Clin Pathol 2006; 126: 916–924
   PubMed Web of Science ®Google Scholar
• Krueger K E, Srivastava S. Posttranslational protein modifications. Mol Cell Proteomics 2006; 5: 1799–1810
   PubMed Web of Science ®Google Scholar
• Wu F, Mo Y Y. Ubiquitin-like protein modification in prostate and breast cancer. Front Biosci 2007; 12: 700–711
   PubMed Web of Science ®Google Scholar
• van Oers J MM, Adam C, Denzinger S, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006; 119: 1212–1215
   PubMed Web of Science ®Google Scholar
• Blaveri E, Brewer J L, Roydasqupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11: 7012–7022
   PubMed Web of Science ®Google Scholar
• Iida S, Rao P H, Ueda R, Chaganti R S, Dalla-Favera R. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma 1999; 34: 25–33
   PubMed Web of Science ®Google Scholar
• Palmisano W A, Crume K P, Grimes M J, et al. Aberrant promoter methylation of transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 2003; 63: 4620–4625
   PubMed Web of Science ®Google Scholar
• Stoehr R, Wild P, Hartmann A. Lasermicrodissection – an important prerequisite for the molecular-genetic analysis of bladder cancer. Pathol Res Pract 2003; 199: 355–362
   PubMed Web of Science ®Google Scholar
• Offersen B V, Knapp M M, Marcussen N, Horman M R, Hamilton-Dutoit S, Overgaard J. Intense inflammation in bladder carcinoma is associated with angiogenesis and indicated good prognosis. Br J Cancer 2002; 87: 1422–1430
   PubMed Web of Science ®Google Scholar
• Leibovici D, Grossman H B, Dinney C P, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005; 23: 5746–5756
   PubMed Web of Science ®Google Scholar
• Kastelan Z, Lukac J, Derezic D, et al. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res 2003; 23: 5185–5189
   PubMed Web of Science ®Google Scholar